IP Library › Granted Patent US 12,589,231
Granted Patent B2
US 12,589,231 · App. 17/435,475 · Granted Mar 31, 2026

Subcutaneously changeable vascular access port

Inventor: Michael Gabriel Tal (Tel Aviv, IL)
Assignee: Portal Access Inc.
A61M39/0208A61M2039/0223A61M2039/0232A61M2205/0216
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,589,231
App. No.
17/435,475
Granted
Mar 31, 2026
Kind
B2
Abstract

Disclosed is a vascular access port selectively changeable subcutaneously from delivery configuration to deployed configuration. The vascular access port includes a port body and a port body extension being partly or wholly disengaged in the delivery configuration, and fixedly connected to form a unified structure of the vascular access port, greater in volume than the port body, in the deployed configuration. Methods and kits for deploying the vascular access port in a body of a subject are also disclosed.

Claims (30)

1 . A vascular access port, comprising:

a port body having a longitudinal axis, coupled with a septum member covering a cavity defined by the port body; and

a deformable port body extension configured to form with the port body a unified structure having final shape and size;

the vascular access port is changeable subcutaneously to a deployed configuration by decreasing in length parallel to the longitudinal axis and/or expanding transversely to the longitudinal axis, wherein the port body extension envelopes a front end and two opposing sides of the port body.

2 . The vascular access port of claim 1 , wherein the unified structure is greater in volume than the port body by at least 15%, and/or has a lower surface area to volume ratio than the combined port body and port body extension when in a delivery configuration, and/or has a base surface area greater than a base surface area of the port body by at least 30%.

3 . The vascular access port of claim 1 , wherein the port body is configured to interlock with the port body extension when the vascular access port is in the deployed configuration.

4 . The vascular access port of claim 1 , wherein the port body extension includes a front edge pointing distally away from the port body and configured to cause atraumatic separation of tissue layers when forced to pass therebetween.

5 . The vascular access port of claim 1 , wherein the port body is configured to deform the port body extension, when the vascular access port changes to the deployed configuration.

6 . The vascular access port of claim 1 , wherein the port body extension is configured to deform when a portion of the port body is pushed against an inner surface of the port body extension.

7 . The vascular access port of claim 1 , wherein the port body extension has lateral edges configured to stretch, separate and/or dissect tissue layers when forced to pass therebetween, when the vascular access port changes to the deployed configuration.

8 . The vascular access port of claim 1 , wherein the port body is configured to maintain size and shape thereof when the vascular access port changes to the deployed configuration.

9 . The vascular access port of claim 1 , wherein the port body extension is configured to stabilize and/or fixate the port body in-place in a target implantation site in the subject body when the vascular access port changes to the deployed configuration.

10 . The vascular access port of claim 1 , wherein the port body has an inferior portion and a posterior portion, the inferior portion surrounds the cavity and the posterior portion is connected to the septum member, wherein the port body extension envelopes the front end and two opposing sides of the port body inferior portion when the vascular access port is in the deployed configuration.

11 . The vascular access port of claim 1 , configured to increase in cross-sectional area when changing to the deployed configuration.

12 . A method for deploying a vascular access port in a body of a subject, the method comprising:

forming a subcutaneous void between or beneath skin tissue layers at a target implantation site in the subject body;

inserting the vascular access port into the subcutaneous void, wherein the vascular access port includes a port body and a deformable port body extension configured to form with the port body a unified structure having final shape and size; and

deploying the vascular access port, wherein the vascular access port changes to a deployed configuration by decreasing in length parallel to the longitudinal axis and/or expanding transversely to the longitudinal axis, wherein the port body extension envelopes a front end and two opposing sides of the port body.

13 . The method of claim 12 , wherein the port body is coupled with a septum member covering a cavity defined by the port body.

14 . The method of claim 12 , wherein the deploying forces an increase in total volume enclosed by the subcutaneous void.

15 . The method of claim 12 , wherein the deploying includes forcing the port body extension to expand laterally by pushing a portion of the port body against an internal surface of the port body extension.

16 . The method of claim 15 , wherein the port body extension has lateral edges configured to shift laterally when the port body extension expands laterally, wherein the deploying includes stretching, separating or dissecting tissue layers forming the subcutaneous void with the lateral edges of the port body extension.

17 . The method of claim 12 , further comprising:

creating a subcutaneous surgical tunnel between a first incision and the target implantation site; and

delivering the vascular access port through the surgical tunnel to the subcutaneous void.

18 . A kit for implanting a vascular access port in a host, the kit comprising:

a vascular access port according to claim 1 ; and

a port delivery apparatus releasably connectable to the port body of the vascular access port according to claim 1 and to the port body extension of the vascular access port according to claim 1 and configured for selectively changing the vascular access port according to claim 1 to the deployed configuration.

19 . A kit according to claim 18 , wherein the port delivery apparatus includes a dissection tip configured for projecting distally relative to distal boundaries of the port body extension when attached to the delivery apparatus body.

20 . A kit according to claim 18 , further comprising a catheter connected or connectable to the port body for facilitating fluid communication between the cavity and a lumen enclosed by the catheter.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2022
From: TAL, MICHAEL GABRIEL
To: PORTAL ACCESS, INC
Reel/Frame 058808/0483 →
Continuity (3)
Provisional Application 62961374 · Jan 15, 2020
Provisional Application 62813073 · Mar 3, 2019
Related Publication 20220134075A1 · May 5, 2022
References Cited (89)
US 4886501A · Johnston et al. · 1989 [cited by applicant]
US 5108377A · Cone et al. · 1992 [cited by applicant]
US 5246424A · Wilk · 1993 [cited by applicant]
US 5387192A · Glantz et al. · 1995 [cited by applicant]
US 5688247A · Haindl et al. · 1997 [cited by applicant]
US 5716326A · Dannan · 1998 [cited by applicant]
US 6033390A · von Dyck · 2000 [cited by applicant]
US 6206871B1 · Zanon et al. · 2001 [cited by applicant]
US 6213973B1 · Eliasen et al. · 2001 [cited by applicant]
US 6258058B1 · Sanfilippo · 2001 [cited by applicant]
US 7445614B2 · Bunodiere et al. · 2008 [cited by applicant]
US 7708722B2 · Glenn · 2010 [cited by applicant]
US 8025639B2 · Powers et al. · 2011 [cited by applicant]
US 8282610B1 · Glenn · 2012 [cited by applicant]
US 8317761B2 · Birk et al. · 2012 [cited by applicant]
US 8545460B2 · Beasley et al. · 2013 [cited by applicant]
US 8608713B2 · Beasley et al. · 2013 [cited by applicant]
US 8876788B2 · Glenn · 2014 [cited by examiner]
US 9381036B2 · Rome et al. · 2016 [cited by applicant]
US 10130503B2 · Couch et al. · 2018 [cited by applicant]
US 10155101B2 · Wiley et al. · 2018 [cited by applicant]
US 20020010442A1 · Teitelbaum · 2002 [cited by applicant]
US 20030018291A1 · Hill et al. · 2003 [cited by applicant]
US 20040133173A1 · Edoga et al. · 2004 [cited by applicant]
US 20040193119A1 · Canaud et al. · 2004 [cited by applicant]
US 20040254537A1 · Conlon et al. · 2004 [cited by applicant]
US 20050137537A1 · Watson et al. · 2005 [cited by applicant]
US 20060217673A1 · Schulze et al. · 2006 [cited by applicant]
US 20070010790A1 · Byrum et al. · 2007 [cited by applicant]
US 20070123831A1 · Haindl et al. · 2007 [cited by applicant]
US 20070161958A1 · Glenn · 2007 [cited by applicant]
US 20080051722A1 · Ellsmere et al. · 2008 [cited by applicant]
US 20080249509A1 · Glenn · 2008 [cited by applicant]
US 20090030373A1 · Gill · 2009 [cited by applicant]
US 20090093765A1 · Glenn · 2009 [cited by applicant]
US 20090221976A1 · Linden et al. · 2009 [cited by applicant]
US 20090259187A1 · Egle et al. · 2009 [cited by applicant]
US 20090306606A1 · Lancette et al. · 2009 [cited by applicant]
US 20100094335A1 · Gerberding et al. · 2010 [cited by applicant]
US 20100262183A1 · Abbott et al. · 2010 [cited by applicant]
US 20100286484A1 · Stellon et al. · 2010 [cited by applicant]
US 20110034886A1 · Elbe et al. · 2011 [cited by applicant]
US 20110213199A1 · Franklin et al. · 2011 [cited by applicant]
US 20110245595A1 · Birk et al. · 2011 [cited by applicant]
US 20110251453A1 · Honaryar et al. · 2011 [cited by applicant]
US 20120059321A1 · Hammond et al. · 2012 [cited by applicant]
US 20120065460A1 · Nitka et al. · 2012 [cited by applicant]
US 20120245536A1 · Gerber et al. · 2012 [cited by applicant]
US 20130012890A1 · Glenn · 2013 [cited by applicant]
US 20130053783A1 · Szweda et al. · 2013 [cited by applicant]
US 20130253263A1 · Nitka et al. · 2013 [cited by applicant]
US 20140276900A1 · Cote et al. · 2014 [cited by applicant]
US 20160106966A1 · Jochum et al. · 2016 [cited by applicant]
US 20160213909A1 · Davey et al. · 2016 [cited by applicant]
US 20160374655A1 · Walters et al. · 2016 [cited by applicant]
US 20170072169A1 · Jochum et al. · 2017 [cited by applicant]
US 20170165464A1 · Jochum · 2017 [cited by applicant]
US 20180214680A1 · Jho et al. · 2018 [cited by applicant]
US 20180264246A1 · Lim et al. · 2018 [cited by applicant]
US 20200028847A1 · Mizuno · 2020 [cited by applicant]
US 20220008706A1 · Tal · 2022 [cited by applicant]
US 20220313972A1 · Tal · 2022 [cited by applicant]
US 20230381479A1 · Tal et al. · 2023 [cited by applicant]
CA 1151489A · 1983 [cited by applicant]
CN 102421395A · 2012 [cited by applicant]
CN 102481201A · 2012 [cited by applicant]
CN 105307716A · 2016 [cited by applicant]
CN 114375214A · 2022 [cited by applicant]
CN 116963797A · 2023 [cited by applicant]
EP 2044889A1 · 2009 [cited by applicant]
GB 2011173820 · 2011 [cited by applicant]
GB 2489518A · 2012 [cited by applicant]
JP H3168159A · 1991 [cited by applicant]
JP 2009536040A · 2009 [cited by applicant]
JP 2013510652A · 2013 [cited by applicant]
WO 2011094712A1 · 2011 [cited by applicant]
WO 2013146307A1 · 2013 [cited by applicant]
WO 2016004217A1 · 2016 [cited by applicant]
WO 2019055037A1 · 2019 [cited by applicant]
WO 2020028847A1 · 2020 [cited by applicant]
WO 2020180854A1 · 2020 [cited by applicant]
WO 2022011020A1 · 2022 [cited by applicant]
WO 2022125661A1 · 2022 [cited by applicant]
U.S. Appl. No. 62/915,973, filed Oct. 16, 2019, Michael Gabriel Tal. [cited by applicant]
International Search Report and Written Opinion mailed Sep. 17, 2020 in International Patent Application No. PCT/US2020/041140. [cited by applicant]
International Search Report and Written Opinion mailed Oct. 22, 2021 in PCT/US2021/040699. [cited by applicant]
Communication pursuant to Article 94(3) EPC mailed on Jun. 16, 2025 in EP 20767305.4. [cited by applicant]
International Search Report, mailed Jun. 10, 2020. [cited by applicant]
ISA Written Opinion, mailing date Jun. 10, 2020. [cited by applicant]